Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2020 from OUS - Section for lung oncology

13 publications found

Abravan A, Eide HA, Helland Å, Malinen E (2020)
Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy
Clin Transl Radiat Oncol, 22, 15-21
DOI 10.1016/j.ctro.2020.02.005, PubMed 32181373

Digernes I, Nilsen LB, Grøvik E, Bjørnerud A, Løvland G, Vik-Mo E, Meling TR, Saxhaug C, Helland Å, Jacobsen KD, Geier O, Emblem KE (2020)
Noise dependency in vascular parameters from combined gradient-echo and spin-echo DSC MRI
Phys Med Biol, 65 (22), 225020
DOI 10.1088/1361-6560/abb71a, PubMed 33200748

Eide IJZ, Helland Å, Ekman S, Mellemgaard A, Hansen KH, Cicenas S, Koivunen J, Grønberg BH, Brustugun OT (2020)
Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)
Lung Cancer, 143, 27-35
DOI 10.1016/j.lungcan.2020.03.009, PubMed 32200138

Frafjord A, Skarshaug R, Hammarström C, Stankovic B, Dorg LT, Aamodt H, Woldbaek PR, Helland Å, Brustugun OT, Øynebråten I, Corthay A (2020)
Antibody combinations for optimized staining of macrophages in human lung tumours
Scand J Immunol, 92 (1), e12889
DOI 10.1111/sji.12889, PubMed 32299134

Haakensen VD, Khadse A, Sandhu V, Halvorsen AR, Solberg SK, Jørgensen LH, Brustugun OT, Kure EH, Helland Å (2020)
Molecular characterisation of TP53 mutated squamous cell carcinomas of the lung to identify putative targets for therapy
Int J Cancer, 147 (10), 2957-2966
DOI 10.1002/ijc.33121, PubMed 32468587

Halvorsen AR, Haugen MH, Öjlert ÅK, Lund-Iversen M, Jørgensen L, Solberg S, Mælandsmo GM, Brustugun OT, Helland Å (2020)
Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients
Front Oncol, 10, 590755
DOI 10.3389/fonc.2020.590755, PubMed 33324562

Halvorsen TO, Stokke K, Killingberg KT, Raj SX, Sørhaug S, Brustugun OT, Fløtten Ø, Helbekkmo N, Hornslien K, Madebo T, Fluge S, Grønberg BH (2020)
Randomized phase III trial comparing switch-maintenance pemetrexed with observation followed by pemetrexed at progression in advanced NSCLC
Acta Oncol, 59 (9), 1051-1057
DOI 10.1080/0284186X.2020.1778179, PubMed 32543258

Koch M, Hjermstad MJ, Tomaszewski K, Tomaszewska I, Hornslien K, Harle A, Arraras J, Morag O, Pompili C, Ioannidis G, Navarra C, Chie W, Johnson C, Bohrer T, Janssens A, Kulis D, Bottomley A, Schulz C, Zeman F, Koller M (2020)
Gender effects on quality of life and symptom burden in patients with lung cancer: results from a prospective, cross-cultural, multi-center study
J Thorac Dis, 12 (8), 4253-4261
DOI 10.21037/jtd-20-1054, PubMed 32944337

Koller M, Shamieh O, Hjermstad MJ, Hornslien K, Young T, Chalk T, Ioannidis G, Harle A, Johnson CD, Tomaszewski KA, Serpentini S, Pinto M, van der Weijst L, Janssens A, Morag O, Chie WC, Arraras JI, Pompili C, Jungraithmayr W, Hechtner M, Katsochi D, Müller K, Gräfenstein L, Schulz C, Bottomley A et al. (2020)
Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study
Lancet Oncol, 21 (5), 723-732
DOI 10.1016/S1470-2045(20)30093-0, PubMed 32213338

Nilsen LB, Digernes I, Grøvik E, Saxhaug C, Latysheva A, Geier O, Breivik B, Sætre DO, Jacobsen KD, Helland Å, Emblem KE (2020)
Responses in the diffusivity and vascular function of the irradiated normal brain are seen up until 18 months following SRS of brain metastases
Neurooncol Adv, 2 (1), vdaa028
DOI 10.1093/noajnl/vdaa028, PubMed 32642687

Öjlert ÅK, Nebdal D, Lund-Iversen M, Åstrøm Ellefsen R, Brustugun OT, Gran JM, Halvorsen AR, Helland Å (2020)
Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer - predictors of response and impact of previous radiotherapy
Acta Oncol, 60 (2), 149-156
DOI 10.1080/0284186X.2020.1854851, PubMed 33356733

Stankovic B, Aamodt H, Bjørhovde HAK, Müller E, Hammarström C, Brustugun OT, Helland Å, Øynebråten I, Corthay A (2020)
The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases
Scand J Immunol, 92 (2), e12893
DOI 10.1111/sji.12893, PubMed 32433774

Umu SU, Langseth H, Keller A, Meese E, Helland Å, Lyle R, Rounge TB (2020)
A 10-year prediagnostic follow-up study shows that serum RNA signals are highly dynamic in lung carcinogenesis
Mol Oncol, 14 (2), 235-247
DOI 10.1002/1878-0261.12620, PubMed 31851411

 
Page visits: 647415